Cosmo Pharmaceuticals NV
SIX:COPN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.8
79.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV
Accrued Liabilities
Cosmo Pharmaceuticals NV
Accrued Liabilities Peer Comparison
PRGO
JAZZ
AVDL
OVB
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Accrued Liabilities
€5.3m
|
CAGR 3-Years
74%
|
CAGR 5-Years
49%
|
CAGR 10-Years
33%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Accrued Liabilities
$533.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
0%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Accrued Liabilities
$858m
|
CAGR 3-Years
14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
18%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Accrued Liabilities
$34.6m
|
CAGR 3-Years
52%
|
CAGR 5-Years
27%
|
CAGR 10-Years
21%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Accrued Liabilities
$2.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Cosmo Pharmaceuticals NV's Accrued Liabilities?
Accrued Liabilities
5.3m
EUR
Based on the financial report for Jun 30, 2024, Cosmo Pharmaceuticals NV's Accrued Liabilities amounts to 5.3m EUR.
What is Cosmo Pharmaceuticals NV's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
33%
Over the last year, the Accrued Liabilities growth was -28%. The average annual Accrued Liabilities growth rates for Cosmo Pharmaceuticals NV have been 74% over the past three years , 49% over the past five years , and 33% over the past ten years .
You don't have any saved screeners yet
